The "Guidelines for Sales Information Activities on Prescription Drugs" (Hanbai-teikyō Guidelines, or "GL") were issued on September 25, 2018 by the Director-General of the Pharmaceutical Safety and Environmental Health Bureau under notification Yaku-sei-hatsu 0925 No. 1. They govern how pharmaceutical companies communicate product information to healthcare professionals (HCPs)—physicians, pharmacists, nurses, and others—for the purpose of promoting the use of their drugs.
This site reads the GL's provisions through two lenses applied to every rule: So what (what the provision means for day-to-day activity) and So why (why the rule was drawn this way). Restating what the GL says is insufficient—understanding why a rule is designed as it is makes it possible to navigate ambiguous situations and recognize when the letter of a rule is being met while its purpose is being defeated.
01Why 2018? — the two problems the GL was written to address
The GL did not emerge from a blank slate. Two categories of documented problems made new rules necessary.
Problem 1: Sales activity left no verifiable record. The dominant form of pharmaceutical promotion in Japan is the representative visit—a face-to-face meeting between a medical representative and a physician, involving verbal explanations and physical materials handed over on the spot. What was said and what was given could not reliably be reconstructed afterward. This made it structurally difficult to verify whether a particular representative's conduct had been appropriate.
Problem 2: The boundary between "academic information" and "promotional activity" was exploited. Representatives were providing physicians with published research articles, competitive comparisons, and information about uses not covered by the approved indication—framed as scientific information sharing rather than promotion. Whether this constituted promotional activity, and if so what was permissible, was not clearly regulated.
So what: The GL's most foundational contribution is closing these gaps. It establishes that all information provision to HCPs for the purpose of promoting drug use—oral, written, or framed as academic—falls within its scope. Neither the medium nor the label changes the regulatory character of the activity.
So why: If evidence of conduct cannot be preserved, enforcement is impossible. If the format of information delivery determines its regulatory status, changing the format becomes a compliance strategy. The GL's design—governing by purpose and substance, not by form—was a deliberate response to both failure modes.
02The GL's four-chapter structure
The GL is organized in four chapters, each addressing a distinct dimension of who is responsible for what.
Chapter 1 — Basic Principles establishes the GL's purpose, scope, and foundational standards: promoting appropriate drug use, grounding information in scientific evidence, and avoiding conduct that misleads HCPs or patients.
Chapter 2 — Company Responsibilities defines what companies must build as organizations: a Review and Supervisory Committee with defined composition and authority, a pre-review process for all materials, training programs for representatives, and systems for recording and retaining evidence of activities.
Chapter 3 — Representative Responsibilities addresses individual conduct: what may be communicated, what is prohibited, how to respond when an HCP asks for information outside the approved indication, and how to handle requests for materials.
Chapter 4 — Supplementary Provisions covers special cases: the exemption for outsourcees and partners (Section 5), the exemption for wholesalers (Section 6), the responsibilities of HCPs (Section 7), and the application dates (Section 8).
So what: The four chapters form a logical stack: purpose (Ch. 1), organizational infrastructure (Ch. 2), individual conduct (Ch. 3), edge cases (Ch. 4). Understanding which chapter addresses which dimension of compliance prevents the confusion of treating all GL provisions as if they operate at the same level.
So why: Individual conduct rules without organizational backing lack enforcement mechanisms. Organizational requirements without individual conduct standards leave representatives without direction. Combining both in a single framework ensures the company's controls and the representative's behavior are coherent—neither can satisfy the GL without the other.
03What the GL regulates — the breadth of "activities"
The GL's scope covers "sales information provision activities for prescription drugs." That phrase is broader than it sounds.
In-person verbal explanations, provision of brochures and product information summaries, presentations, telephone calls, emails, websites, and reprints of published articles—any channel through which a company provides information to HCPs with the intent to promote drug use is covered. The medium does not determine whether the GL applies; the purpose does.
Medical information activities—responses to unsolicited HCP inquiries—are not automatically within scope, but the line between "responding to an inquiry" and "promoting a drug" is determined by substance and context, not by what either party calls the interaction.
So what: The GL's reach is not determined by the format of the interaction. Claiming an activity is "educational" or "academic" does not place it outside the GL if the underlying purpose is promotion.
So why: Scope defined by format invites format shopping. If oral explanations were outside the GL, companies would shift from written to verbal. If academic framing were sufficient to exclude an interaction, every promotional visit would be relabeled a scientific exchange. Defining scope by purpose and substance makes the GL resistant to structural evasion.
04Why so-what and so-why
Reading a GL provision in its original language often leaves the practical question unanswered. "A Review and Supervisory Committee shall be established" does not tell you what the committee must scrutinize, under what conditions it should reject a material, or how to evaluate a borderline case.
Every provision discussed on this site is accompanied by two explicit analyses.
So what — what the provision means operationally: what changes in the field, what becomes permissible, what becomes prohibited, and where the conditions are.
So why — the rule's design rationale: what problem it prevents, what would happen without it, and why the specific conditions were set where they were.
So what: Understanding the rationale behind a rule is the difference between checking a box and actually complying. When the rationale is clear, grey areas can be navigated by asking: "Does this action serve or undermine the reason the rule exists?"
So why: Rules without rationale produce compliance theater—formal adherence that defeats the rule's purpose. Rationale-aware compliance is more durable and more accurate, because it is the only kind that generalizes beyond the specific scenarios the rulemaker anticipated.
Each chapter and section page provides a substantive explanation of the GL's provisions alongside so-what/so-why analysis. The pages covering Chapters 2 and 3, the outsourcee exemption (Section 4.5), the wholesaler exemption (Section 4.6), HCP responsibilities (Section 4.7), and the application dates (Section 4.8) are designed to be read independently—but for readers encountering the GL for the first time, Chapter 1 is the right starting point.